ID
45182
Description
Principal Investigator: Mark Purdue, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department Health and Human Services, Bethesda, MD, USA MeSH: Carcinoma, Renal Cell,Kidney Neoplasms https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000351 The National Cancer Institute (NCI) genome-wide association study (GWAS) of renal cell carcinoma (RCC) was conducted to investigate common genetic variants associated with RCC risk. The GWAS includes 1,453 RCC cases and 3,531 controls of European background from 4 studies (3 cohort, 1 case-control), scanned using the Illumina InfiniumHumanHap 550, 610 and 660W chips. This project was supported by the Intramural Research Program of the National Institutes of Health and NCI. Data from this GWAS were pooled with those from another GWAS of RCC (2,639 cases and 5,392 controls) conducted in Europe by the International Agency for Research on Cancer and the Centre National de Gènotypage. Findings from this collaboration are described in an upcoming report (Purdue et al. Nature Genetics 2011;43(1):60-65; PMID: 21131975). Only data from the NCI scan are included in this dbGaP submission.
Lien
Mots-clés
Versions (2)
- 20/08/2022 20/08/2022 - Simon Heim
- 12/10/2022 12/10/2022 - Adrian Schulz
Détendeur de droits
Mark Purdue, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department Health and Human Services, Bethesda, MD, USA
Téléchargé le
12 octobre 2022
DOI
Pour une demande vous connecter.
Licence
Creative Commons BY 4.0
Modèle Commentaires :
Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.
Groupe Item commentaires pour :
Item commentaires pour :
Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.
dbGaP phs000351 NCI Genome-Wide Association Study of Renal Cell Carcinoma
Eligibility Criteria
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID, consent group, and affection status of participants with or without renal cell carcinoma.
- Sample ID and subject ID of participants with or without renal cell carcinoma.
- Subject ID, study design [cohort study or case-control study], affection status, and gender of participants with or without renal cell carcinoma.
Similar models
Eligibility Criteria
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID, consent group, and affection status of participants with or without renal cell carcinoma.
- Sample ID and subject ID of participants with or without renal cell carcinoma.
- Subject ID, study design [cohort study or case-control study], affection status, and gender of participants with or without renal cell carcinoma.
C1518424 (UMLS CUI [1,2])
C0043157 (UMLS CUI [1,3])
C0021430 (UMLS CUI [1,2])
C1271092 (UMLS CUI [1,2])
C0740457 (UMLS CUI [1,3])